High-throughput live-cell screens are intricate elements of systems biology studies and drug discovery pipelines. Here, we demonstrate an optogenetics-assisted method that obviates the addition of chemical activators and reporters, reduces the number of operational steps and increases information content in a cell-based small molecule screen against human protein kinases including an orphan receptor tyrosine kinase. This blueprint for all-optical screening can be adapted to many drug targets and cellular processes.
manipulate the behavior of cells and animals non-invasively and with high spatial and temporal precision [5] [6] [7] . Here, we developed an optogenetics-assisted, cell-based screening method that interrogates receptor tyrosine kinases (RTKs) and the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway comprising one Gprotein (Ras) and three intracellular kinases (Raf, MEK and ERK). We demonstrate that in this screening method the use of light for activation and detection of cell signaling obviated the need for addition of reagents, limited the number of operational steps and provided new strategies to increase specificity and counter variability.
The MAPK/ERK pathway is activated by RTKs and regulates cell survival, proliferation and differentiation. Modulators of the MAPK/ERK pathway, RTKs and other protein kinases are pursued as new therapeutics in cancer and metabolic and neurodegenerative disorders. We first engineered human embryonic kidney 293 (HEK293) cells that contain light-activated RTKs and a genetic fluorescent MAPK/ERK pathway reporter (Fig. 1a) . The light-activated RTKs (also called 'Opto-RTKs') are modified growth factor receptors that are insensitive to their natural ligands but activated by blue light-induced homodimerization through incorporation of the light-oxygen-voltage-sensing (LOV) domain of aureochrome1 from V. frigida 8 (Supplementary Results, Supplementary Fig. 1 ). We initially employed two OptoRTKs, the light-activated murine fibroblast growth factor receptor 1 (Opto-mFGFR1) and the light-activated human epidermal growth factor receptor (Opto-hEGFR). In the fluorescent reporter (SRE-GFP), tandem repeats of serum response element (SRE) 9 , an enhancer sequence responsive to signaling pathways including the MAPK/ERK pathway, precede a gene coding for the green fluorescent protein (GFP). The engineered cells respond to light at a wavelength and intensity suited for Opto-RTK activation (λ~470 nm, intensity~200 μW/cm 2 ) with increased production of GFP ( Fig. 1b and Supplementary Fig.  2 ), and combining Opto-RTKs and GFP reporter thus enables a novel 'all-optical' mode of operation where light was used to activate as well as read cellular signaling. Using this mode of operation, we were able to screen small molecules in the 384-well plate format without addition of reagents to induce or detect pathway activation and with few handling steps ( Fig.  1c and Supplementary Fig. 3 ). This assay was robust (Z'-factor ≥ 0.7, Materials and Methods) and not influenced by ambient light ( Supplementary Fig. 4 ) or bleaching ( Supplementary Fig. 5 ). In addition, all wells in the 384-well plate were activated at the same time and with nearly identical intensity using light emitting diodes (LEDs) (deviation of intensity <0.05% over the plate, day-to-day variability <0.05%). In a set of kinase inhibitors (Supplementary Table 1 ), three molecules inhibited the mFGFR1-MAPK/ERKaxis by >50%, and these molecules are known kinase inhibitors of FGFR1 or of MAPK/ERK pathway components (Fig. 1c, d and Supplementary Fig. 6 ). To demonstrate the ability to identify whether ligands act at the receptor or downstream pathway, we conducted the same screen with Opto-hEGFR. Unlike FGFR1, which couples to the MAPK/ERK pathway via additional FGFR substrate adaptor proteins, EGFR directly activates it. Three molecules inhibited the EGFR1-MAPK/ERK-axis, and these molecules are known kinase inhibitors of EGFR or pathway components (Fig. 1d) . Because inhibitors of FGFR1 were not detected in the screen with EGFR and vice versa, the method selectively identified those small molecules that specifically act on receptors or common downstream proteins. Collectively, these results demonstrate a cell-based small molecule screen in the 384-well format assisted by optogenetics. The method functions without added reagents and a reduced number of operational steps as physical contact to the living cells was not required.
Because peptides or other agonists are not required, the all-optical method can also screen against 'orphan' receptors, i.e. receptors for which native ligands are not known. To demonstrate optical control of an orphan receptor, we first identified human orphan RTKs through de novo database and bioinformatics analysis (Supplementary Fig. 7 ). The database search reported human ROS1 (hROS1), a proto-oncogene orphan RTK that is activated by protein fusion in a variety of tumor cell types 10, 11 . To engineer a light-activated variant of human hROS1 (Opto-hROS1), we fused the dimerizing LOV domain to the intracellular domain of hROS1 ( Supplementary Fig. 8 ). When testing the kinase inhibitor library against Opto-hROS1, we found three molecules that inhibited the hROS1-MAPK/ERK-axis ( Supplementary Fig. 9 ). Two of these molecules (crizotinib and GSK-1120212) are known kinase inhibitors of hROS1 and pathway components. The third molecule (AV-951 12 ) was active specifically against hROS1 but not mFGFR1 or hEGFR ( Supplementary Fig. 10 ). Notably, AV-951 was previously not assigned to inhibit hROS1.
We next extended the method to increase information content in cell-based screens. First, we demonstrate that a second, spectrally-distinct FP (e.g. mKate2 13 ) can be incorporated and detected separately from GFP ( Supplementary Fig. 10 ). If expressed constitutively, this second protein can report small molecules that inhibit gene transcription and protein translation/folding 14 , potential assay confounders. As GFP exhibits fluorescence in the same wavelength range as many small molecules in screening collections, a red FP may generally improve assay performance. Second, we tested whether the ability to spatially focus activation can improve the method. Stimulation of optogenetic tools is often realized using custom-built hardware and continuous illumination [15] [16] [17] . However, microplate readers commonly part of screening platforms employ discontinuous flash lamps. We thus tested if flashes provide sufficient intensity to activate optogenetic proteins and found that 900 blue light flashes (2 μs duration, 9 W average power of lamp) resulted in robust MAPK/ERK pathway activation in SPC212 cells expressing Opto-mFGFR1 ( Fig. 2a to c) . Using a light guide-lens assembly, we then confined flash lamp stimulation to the center of single wells (area~3.14 mm 2 ) while leaving the well periphery unstimulated (Fig. 2d, e) . We thereby created two cell populations (activated center population and silent peripheral population) within each well, and we exploited these populations to obtain high-content measurements. When testing small molecules, we found that inactive molecules left centers activated and peripheries silent, inhibitory molecules resulted in silent centers and silent peripheries, and activators resulted in activated centers and activated peripheries (Fig. 2f) . This result showed that probing two cell populations in a single well was sufficient to test for inhibitory or activating effects of a small molecule. In further experiments, one cell population may also serve as a local control for others. Because trial and control are performed under identical conditions in the same well, the influence of environmental perturbations on measurement outcome may be reduced. These experiments can be directly transferred to high-throughput platform microplate readers without the need for specialized instrumentation.
In summary, we demonstrate that incorporation of optogenetics enabled cell-based small molecule screens without additives but minimal operational steps and increased information content. Light acted as a universal ligand for receptors of different families (e.g. FGFR1, EGFR or ROS1), but, at the same time, was specific to stimulate the genetically-engineered receptors. Interference from endogenous receptors that may be also activated by added ligands can be excluded, which is particularly desirable when targeting receptors for which specific ligands are not available. For instance, in our experiments EGF or FGF2 will have bound to several receptor proteins expressed in these cells (FGFR1, FGFR2, FGFR3, FGFRlike 1 and EGFR), while Opto-RTK activation was specific to the engineered receptor. Activation by light may be in in real-time to reveal new insights into molecular inhibition and cellular signaling mechanisms. For instance, the interaction between small molecules and proteins can be activation-state dependent 18, 19 , and the duration and frequency of activation can determine choice of pathway or functional outcome 20, 21 . The ability to switch signals on with temporal precision and tunable strength, even within one well, may explore these phenomena in a systematic and automated manner. This may be of particular use when exploring 'mutagenesis space' in genetic libraries and the method is compatible with transient cell transfection. We further foresee the extension and adaptation of this approach to other drug targets to be straightforward because of an increasing number of available optogenetic tools and fluorescent reporters.
Online Methods

Kinase inhibitor library
Small molecules are listed in Supplementary Table 1 . Out of the tested 68 small molecules, 62 molecules target protein kinases.
Gene constructs
Opto-mFGFR1 and Opto-hEGFR in pcDNA3.1(-) (Life Technologies) were described previously 8 . Identification of ROS1 and genetic engineering of Opto-hROS1 is described below. The SRE-GFP reporter vector and the vector containing MonsterGFP under the control of the CMV promoter were obtained from Qiagen/SA Biosciences. mKate2 was obtained from D.M. Chudakov (Shemiakin-Ovchinnikov Institute of Bioorganic Chemistry)/ Evrogen 13 and subcloned into pcDNA3.1(-) using polymerase chain reaction.
Cell culture and transfection
Malignant pleural mesothelioma SPC212 cells were kindly provided by R. Stahel (University of Zurich) and HEK293 were derived by F.L. Graham (McMaster University). Malignant pleural mesothelioma SPC212 cells stably expressing Opto-mFGFR1 8 and HEK293 cells were maintained in RPMI1640 and DMEM, resp., in a humidified incubator with 5% CO 2 atmosphere. Media were supplemented with 10% FBS, 100 U/ml penicillin and 0.1 mg/ml streptomycin, and RPMI1640 was additionally supplemented with 2 mM LGlutamine. For transfection of HEK293 cells, 2×10 6 cells were seeded in 60 mm cell culture dishes coated with poly-L-ornithine (PLO, Sigma). Cells were transfected with 4.04 to 8.04 μg total DNA per dish (receptor, pcDNA3.1(-) empty vector, and reporter at a ratio of 1:50:50 or 1:100:100) using polyethylenimine (Polysciences). For mock transfected cells (Fig. 1b and Supplementary Fig. 2, "HEK293") , receptor vector was omitted in the transfection mixture. For experiments with mKate2 13 (Supplementary Fig. 11 ), empty vector was substituted by mKate2 in pcDNA3.1(-). For control experiments with MonsterGFP ( Supplementary Fig. 5 ), reporter vector and receptor vector was substituted by vector containing MonsterGFP under the control of the CMV promoter.
Custom incubator for light stimulation of well plates
A thermoelectric incubator (PT2499, ExoTerra) was equipped with 300 RGB LEDs (5050SMD, λ max ≈ 630 nm (red light), λ max ≈ 530 nm (green light), λ max ≈ 470 nm (blue light), bandwidth ≈ ± 5 nm). Light intensity was controlled with a dimmer and measured with a digital power meter (PM120VA, Thorlabs). Blue light intensity at maximal output was 247 μW/cm 2 . Light of this intensity is sufficient for activation and well tolerated by mammalian cells without signs of toxicity even for extended periods of time. Hardware to maintain a CO 2 atmosphere is not required if medium supplemented with HEPES (25 mM) is used during light stimulation (see below). To measure profile of light distribution, the sensor of the power meter was mounted on a holder and moved in 1 cm steps. Intensity was recorded and deviation between highest and lowest intensity was calculated (Δ<0.13 μW/ cm 2 ). Day-to-day variability of light was measured in the same way but on several days distributed over one week (Δ<0.13 μW/cm 2 ). For evaluation of the effect of ambient light ( Supplementary Fig. 4 ), cells were stimulated immediately after seeding with white light of comparable intensity to that encountered in a dim room.
All-optical drug screening against RTKs and the MAPK/ERK pathway
The workflow is depicted in Supplementary Fig. 3 . Transfected HEK293 cells were kept in DMEM (supplemented with 5% FBS and no antibiotics; "D5-AB" medium) for 6 h. Afterwards, 5'000 to 20'000 cells were seeded in each well of 384-well plates (3712, Corning) in low-fluorescence medium (FlouroBrite ™ , Life Technologies, supplemented with 25 mM HEPES, 0.5% FBS, 100 U/ml penicillin and 0.1 mg/ml streptomycin, pH 7.5; "COI" medium). Small molecules were added and after 1 h cells were stimulated with blue light in a custom incubator (see above). Unstimulated cells were kept in the dark by covering selected wells on the same 384-well plate. GFP fluorescence was then measured in a microplate reader (Synergy H1, BioTek) at the optimized excitation wavelength of 500 ± 5 nm and emission wavelength of 535 ± 5 nm (10 measurements per well, measurement duration: 10 ms, gain: 90 to 130). We found that 384-well plates exhibit fluorescence in the blue-green part of the light spectrum ( Supplementary Fig. 11 ), and optimization of the excitation wavelength allowed for improved signal to noise ratio. mKate2 fluorescence was measured at excitation wavelength of 570 ± 5 nm and emission wavelength of 660 ± 5 nm.
Identification of Orphan RTKs
Orphan RTKs were identified using the bioinformatics procedure described in Supplementary Fig. 7 . Protein family search with the PFAM motif "Pkinase_Tyr" (PF07714) at the Wellcome Trust Sanger Institute (http://pfam.xfam.org/) 22 retrieved a comprehensive list of human Tyr kinases. This PFAM motif is a good representative of kinase domains found in RTKs (we confirmed that it is found in members of diverse RTK families, such as fibroblast growth factor receptors, ErbB receptors, Insulin-like growth factor receptor, neurotrophin receptors, ROR receptors). Retrieval of these sequences was followed by transmembrane helix prediction with TMHMM 23 to retain only sequences with transmembrane helices. To remove sequence redundancy and assign sequence fragments clustering with UCLUST 24 was performed. 69 clusters with a unique candidate sequence each for RTKs were obtained Supplementary Table 2 and orphan RTKs were identified by manual curation.
Genetic engineering of Opto-ROS1
A sequence coding for the ROS1 gene was obtained from the Mammalian Gene Collection (Dharmacon, GE Life Science). Using inverse PCR, an expression vector was prepared starting from an Opto-mFGFR1 vector in which the mFGFR1 ICD was replaced by two inverted SapI restriction sites. The ROS1 ICD was amplified with oligonucleotides (F: GAT CGC TCT TCA GAC CAT AGA AGA TTA AAG AAT CAA AAA AG, R: GAT CGC TCT TCC AGG ATC AGA CCC ATC TCC ATA TCC ACT G) and PCR and inserted into the vector using 'Golden Gate' cloning 25 .
Activation of Opto-RTKs in microplate reader and ERK1/2 phosphorylation 5×10 4 cells per well were seeded in 48-well plates coated with PLO and starved for 24 h in medium containing 0.1% FBS. Small molecules or EGF (5.5 ng/ml) were added to the cells one h prior to onset of light stimulation. A microplate reader equipped with monochromators (Synergy H1, BioTek; 9 W average power of flash lamp, 2 μs flash duration) was repurposed for spatially-confined light stimulation and read-out. For stimulating entire wells, the device's area scanning mode was configured for a 3×3 matrix with horizontal and vertical point spacing of 2 mm. This protocol was repeated 100 times. For stimulating well centers, the device's area scanning mode was configured for a 9×9 matrix with minimal point spacing. This protocol was repeated three times. In both protocols, bottom illumination at an excitation wavelength of 470 nm was applied. Cells were then fixed and permeabilised in a solution containing 4% formaldehyde and 1% methanol for 15 min. After washing with PBS three times for 5 min, cells were blocked in 1% BSA, 0.1% Tween in PBS for 30 min and incubated with anti-pERK1/2 (#9101, Cell Signaling Technology, 1:500) for 1 h. After washing with PBS three times for 5 min, signal was developed using the UltraVision LP detection system (Thermo Scientific) and 3,30-diaminobenzidine as chromogen. For readout, the device's area scanning mode was configured for a 3×3 with spacing of 3 mm. In some experiments, this protocol was repeated three times with absorbance measurements at 450 nm. Data were normalized to EGF-treated wells and background (SPC212 cells in the dark) was subtracted. Photographs were acquired with a macroscope 26 . This approach can also be used for blue light activation of gene transcription using a different optogenetic system (see below).
Optimization of excitation wavelength for microplate reader GFP measurements
The microplate reader was used to quantify fluorescence of 384-well plates filled with lowfluorescence media. Emission spectra were acquired at several fixed excitation wavelengths ( Supplementary Fig. 12 ). Supplementary Fig. 1 and Supplementary Fig. 8 ) and a MAPK/ERK pathway-responsive GFP reporter (SRE-GFP). In all-optical screening, effects of small molecules (e.g. receptor inhibitors or pathway inhibitors) are tested in 384-well plates by first activating the RTK with blue light (λ~470 nm, I~200 μW/cm 2 ) followed by detection of pathway activity using the GFP reporter. In cells treated with inhibitors of RTKs or of components of the MAPK/ERK pathway, GFP expression will be absent. Except for small molecule addition, the process does not require contact to the cells, solution exchange or added reagents (Supplementary Fig. 3 
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